Volume 16, Issue 1 (March 2024 2024)                   Iranian Journal of Blood and Cancer 2024, 16(1): 59-66 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghasemi Z, Abolghasemi H, Babaei F, Cheraghali A M, Yousefi N. Plasma Production in Iran: Streaming Towards Plasma Self-sufficiency. Iranian Journal of Blood and Cancer 2024; 16 (1) :59-66
URL: http://ijbc.ir/article-1-1484-en.html
1- Ph.D. Student of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Professor of Pharmacology, Board member of Iranian Academy of Medical Sciences, Iranian Academy of Medical Sciences, Tehran, Iran
5- Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran , n.yousefi@sbmu.ac.ir
Abstract:   (651 Views)
Introduction: The role of Plasma-Derived Medicinal Products (PDMPs) in managing life-threatening diseases is remarkable. Human plasma as a raw material for PDMPs is obtained from volunteers through apheresis or whole blood collection. The global PDMPs market in 2021 shows an average annual growth rate of 7.4% since 1996 which is higher than the average annual pharmaceutical market growth rate. In line with WHO policies, Iran has improved its national voluntary non-remunerated donors (VNRD) program to supply the local PDMPs market. This study shows the 10-year Iran PDMPs market evolution to assess its self-sufficiency.
Method: We conducted a cross-sectional study from 2012 to 2021 to assess the self-sufficiency rate of Iran’s plasma industry for PDMPs including Albumin, Immune globulins, and Antihemophilic Factors. In addition, we show the gap between market supply and demand to lighten the self-sufficiency future.
Result: The annual growth rate of total collected plasma was 18.9% over 10 years in Iran from 2012 to 2021. Although the consumption rate of intravenous Immune globulins has increased from 777 kg to 2,108 Kg, due to a significant increase in local plasma production, its self-sufficiency rate increased from 53% to 93%.  Similarly, the demand rate for Albumin grew from 21% in 2012 to 90% in 2021.
Discussion: Although local plasma production in Iran significantly provided plasma self-sufficiency as a raw material, local market demand for PDMPs is mainly supplied through contract fractionation with European fractionators.  Access to complete self-sufficiency in Iran needs increasing plasma production, as well as developing major local plasma fractionators.
Full-Text [PDF 609 kb]   (86 Downloads)    
: Original Article | Subject: Adults Hematology & Oncology
Received: 2023/12/18 | Accepted: 2024/02/20 | Published: 2024/03/25

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb